Orikine Bio Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$6.67M
- Investors
-
3
Orikine Bio General Information
Description
Developer of cytokine-based therapies designed for the treatment of autoimmune and inflammatory diseases. The company engages in advancing the field of engineered cytokines with biological features for the treatment of immune-mediated diseases, enabling clients to avuil therapies that have the power to reshape the lives of patients around the globe.
Contact Information
Website
www.orikine.bioCorporate Office
- Barcelona Science Park Tower D Building
- C/Baldiri Reixac, 4-8
- 08028 Barcelona
- Spain
Corporate Office
- Barcelona Science Park Tower D Building
- C/Baldiri Reixac, 4-8
- 08028 Barcelona
- Spain
Orikine Bio Timeline
Orikine Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 24-Jul-2025 | $6.67M | Completed | Generating Revenue | ||
| 2. Seed Round | 18-Jul-2023 | Completed | Generating Revenue | |||
| 1. Seed Round | 31-Oct-2022 | $737K | $737K | Completed | Generating Revenue |
Orikine Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Orikine Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orikine Bio Patents
Orikine Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026167214-A1 | Cytokine targeting myeloid cells | Pending | 06-Feb-2025 | ||
| WO-2026167218-A1 | Dual csf1-il-10 cytokine comprising an immunoglobulin fc fragment | Pending | 06-Feb-2025 | ||
| WO-2026167215-A1 | Dual il-34-il-10 cytokine | Pending | 06-Feb-2025 | ||
| AU-2024315544-A1 | Dual csf1-il-10 cytokine | Pending | 03-Aug-2023 | ||
| EP-4755906-A2 | Dual csf1-il-10 cytokine | Pending | 03-Aug-2023 | C07K14/5428 |
Orikine Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orikine Bio Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| INNVIERTE SICC | Government | Minority | ||
| AdBio partners | Venture Capital | Minority | ||
| Asabys Partners | Venture Capital | Minority |
Orikine Bio FAQs
-
When was Orikine Bio founded?
Orikine Bio was founded in 2022.
-
Where is Orikine Bio headquartered?
Orikine Bio is headquartered in Barcelona, Spain.
-
What is the size of Orikine Bio?
Orikine Bio has 10 total employees.
-
What industry is Orikine Bio in?
Orikine Bio’s primary industry is Clinics/Outpatient Services.
-
Is Orikine Bio a private or public company?
Orikine Bio is a Private company.
-
What is Orikine Bio’s current revenue?
The current revenue for Orikine Bio is .
-
How much funding has Orikine Bio raised over time?
Orikine Bio has raised $13.5M.
-
Who are Orikine Bio’s investors?
INNVIERTE SICC, AdBio partners, and Asabys Partners have invested in Orikine Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
